Abstract
Evidence suggests an association between serotonin reuptake inhibitors (SRIs) and accelerated bone loss. SRIs and bone metabolism share a common serotonergic mechanism, generating the hypothesis that genetic variation in the serotonin system might modulate bone metabolism changes during SRI treatment. We examined functional genetic polymorphisms within serotonin receptors involved in bone metabolism, to determine whether they predict changes in bone metabolism during SRI treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have